Chronic Lymphocytic Leukemia

New data reveals bexobrutideg shows promising efficacy and safety in treating relapsed/refractory chronic lymphocytic leukemia, offering hope for patients.

Pirtobrutinib shows significant improvements in patient-reported outcomes for relapsed CLL/SLL, outperforming standard therapies in a recent trial.

DZD8586 achieved a high response rate in patients with relapsed/refractory CLL/SLL.

Paolo Ghia, MD, PhD, discusses results from the final analysis of the CAPTIVATE study in CLL/SLL.

During a live event, Danielle M. Brander, MD, discussed use of zanubrutinib in high-risk chronic lymphocytic leukemia.

Paolo Ghia, MD, PhD, discusses the final analysis of the CAPTIVATE study.

During a live event, John S. Renshaw, MD, and other oncologists discussed various trials of novel regimens for patients with chronic lymphocytic leukemia.

The FDA has approved a tablet version of zanubrutinib for all indications, improving convenience and reducing pill burden for patients with blood cancers.

The CAPTIVATE trial reveals long-term survival benefits of fixed-dose ibrutinib plus venetoclax for chronic lymphocytic leukemia patients, including high-risk groups.

Most CRS, ICANS, and neuro events after liso-cel were mild and occurred within 15 days post-infusion, according to different clinical trial and real-world settings.

Zanubrutinib shows durable efficacy in CLL/SLL with 17p deletions, according to 5-year SEQUOIA trial data.

A zanubrutinib, venetoclax, and obinutuzumab triplet achieved deep remissions and high undetectable measurable residual disease rates in relapsed CLL.

Statin use in CLL/SLL patients showed improved survival regardless of treatment, suggesting repurposing potential for this accessible drug.

During a live event, Shuo Ma, MD, PhD, discussed the resistance mutation analysis of patients who had disease progression after receiving pirtobrutinib for BTK inhibitor–pretreated chronic lymphocytic leukemia.

During a live event, Shuo Ma, MD, PhD, discussed the outcomes of the BRUIN trial of pirtobrutinib in BTK inhibitor–pretreated chronic lymphocytic leukemia.

Ahmad Abuhelwa, MD, discusses the significance of a study exploring statin use in patients with chronic lymphocytic leukemia.

Ahmad Abuhelwa, MD, discusses an analysis exploring the connection between statins and better outcomes in patients with CLL and SLL.

Ahmad Abuhelwa, MD, discusses the mechanisms of statins and how they can play a surprisingly beneficial role in patients with chronic lymphocytic leukemia.

Fewer prior therapies with liso-cel in chronic lymphocytic leukemia showed improved overall response rate in TRANSCEND-CLL-004 analysis.

During a live event, Marc S. Hoffmann, MD, discussed outcomes from the SEQUOIA and ELEVATE-TN studies in chronic lymphocytic leukemia.

During a Case-Based Roundtable® event, John N. Allan, MD, discussed the addition of anti-CD20 antibody and the use of MRD following fixed-duration treatment of chronic lymphocytic leukemia.

During a Case-Based Roundtable® event, John N. Allan, MD, discussed how new regimens using BTK inhibitors and venetoclax might be used in patients with chronic lymphocytic leukemia.

During a Case-Based Roundtable® event, Ryan W. Jacobs, MD, discussed a patient who received 2 prior lines of therapy for chronic lymphocytic leukemia.

The CRISTALLO trial showed that venetoclax plus obinutuzumab achieved high minimal residual disease negativity as a frontline chronic lymphocytic leukemia therapy.

During a Case-Based Roundtable® event, Nitin Jain, MD, and participants discussed treating a patient with CLL after acalabrutinib and venetoclax/rituximab.